Headlines about Keryx Biopharmaceuticals (NASDAQ:KERX) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Keryx Biopharmaceuticals earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.882369622555 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the media headlines that may have effected Accern’s scoring:

KERX has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, December 1st. Stifel Nicolaus cut their price objective on Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating for the company in a report on Wednesday, November 8th. Finally, ValuEngine lowered Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, September 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $7.44.

Shares of Keryx Biopharmaceuticals (KERX) traded down $0.01 during trading hours on Friday, hitting $4.74. The company had a trading volume of 789,100 shares, compared to its average volume of 1,078,150. The company has a current ratio of 4.46, a quick ratio of 3.76 and a debt-to-equity ratio of 13.95. Keryx Biopharmaceuticals has a twelve month low of $4.33 and a twelve month high of $8.38. The stock has a market capitalization of $556.93, a price-to-earnings ratio of -3.16 and a beta of 4.92.

Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.03). Keryx Biopharmaceuticals had a negative return on equity of 544.63% and a negative net margin of 156.70%. The firm had revenue of $15.00 million for the quarter, compared to analysts’ expectations of $18.88 million. During the same quarter in the prior year, the business posted ($0.39) earnings per share. Keryx Biopharmaceuticals’s revenue was up 138.1% on a year-over-year basis. sell-side analysts anticipate that Keryx Biopharmaceuticals will post -1.36 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.dailypolitical.com/2018/01/12/keryx-biopharmaceuticals-kerx-getting-somewhat-favorable-press-coverage-accern-reports.html.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Insider Buying and Selling by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.